Successful treatment with liposomal amphotericin B of an intraabdominal abscess due to Candida norvegensis associated with a Gore-Tex mesh infection

Scandinavian Journal of Infectious Diseases

Volumn 32, Issue 5, 2000, Pages 560-562

  Nolla Salas, J ^a   Torres Rodriguez J M ^b   Grau, S ^a   Isbert, F ^a   Torrella, T ^c   Riveiro, M ^a   Sitges Serra, A ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Institut Municipal d'InvestigacióMèdica

^c Catalonia Reference Laboratory   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; CEFEPIME; CORTICOSTEROID; FLUCONAZOLE; IMIPENEM; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POLITEF; VANCOMYCIN; VORICONAZOLE;

ABDOMINAL ABSCESS; ABDOMINAL WALL CLOSURE; ABSCESS DRAINAGE; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA NORVEGENSIS; CANDIDIASIS; CASE REPORT; COLOSTOMY; CONFUSION; DRUG INFUSION; DRUG TOLERANCE; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; ILEOSTOMY; LAPAROTOMY; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; OLIGURIA; PELVIS ABSCESS; REOPERATION; SURGICAL EQUIPMENT; SUTURE; TACHYCARDIA; TACHYPNEA; TREATMENT OUTCOME; WOUND DEHISCENCE; WOUND HEALING;

EID: 0033790317     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655400458893     Document Type: Article

References (10)

1. Fungal infection in surgical patients
2. Surgical infections: Prevention and treatment, 1965 to 1995
3. Significance of yeasts recovered from intraabdominal specimens in patients with gastrointestinal perforations
4. Candida norvegensis: A fluconazole-resistant species
5. Invasive candida norvegensis infection in immunocompromised patients
6. Candida norvegensis peritonitis and invasive disease in a patient on continuous ambulatory peritoneal dialysis
7. Isolation of Candida norvegensis from clinical specimens: Four case reports
8. Fluconazole failure in the treatment of invasive mycoses
9. Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options
10. Lipid formulations of amphotericin B: Clinical efficacy and toxicities